Pulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Tuesday. The firm issued a hold rating on the biotechnology company’s stock.

Pulmatrix Stock Up 16.7 %

NASDAQ PULM opened at $7.34 on Tuesday. Pulmatrix has a 52 week low of $1.55 and a 52 week high of $8.44. The business’s fifty day simple moving average is $2.92 and its 200-day simple moving average is $2.34. The firm has a market cap of $26.79 million, a PE ratio of -2.78 and a beta of 0.99.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.